藿苏养胃口服液干预阿帕替尼治疗进展期胃癌不良反应  

Clinical Efficacy of Huosu Yangwei Oral Liquid in Treatment of Adverse Reactions of Advanced Gastric Cancer with Apatinib

作　　者：周宇轩 方盛泉[1,2] 周悦 齐梅 张梦圆 李富龙 邓玉海[1,2] 王轶[1,2] 秦艺文[1,2] 王宏伟[1,2] ZHOU Yuxuan;FANG Shengquan;ZHOU Yue;QI Mei;ZHANG Mengyuan;LI Fulong;DENG Yuhai;WANG Yi;QIN Yiwen;WANG Hongwei(Shanghai University of Traditional Chinese Medicine,Shanghai China 201203;Yueyang Hospital of Integrated Traditional Chinese and Western Medicine,Shanghai University of Traditional Chinese Medicine,Shanghai China 200437)

机构地区：[1]上海中医药大学,上海201203 [2]上海中医药大学附属岳阳中西医结合医院,上海200437

出　　处：《中医学报》2023年第6期1296-1302,共7页Acta Chinese Medicine

基　　金：上海市自然科学基金项目(20ZR145930);上海申康中心临床培育项目(SHD12018X30);上海中医药大学附属岳阳中西医结合医院院级重点基金项目(2019YY201);上海中医药大学附属岳阳中西医结合医院面上特别基金项目(2021yygm06)。

摘　　要：目的:观察藿苏养胃口服液干预阿帕替尼治疗进展期胃癌不良反应的临床疗效。方法:64例脾气虚证进展期胃癌患者按照随机数字表法平均分为试验组和对照组。对照组给予阿帕替尼,试验组在对照组治疗基础上给予藿苏养胃口服液。两组均治疗两个疗程(42 d),比较两组患者不良反应发生率、生存质量及疾病控制率。结果:(1)治疗期间,试验组不良反应发生率低于对照组(66.67%vs 90.00%,χ~2=4.812,P<0.05)。(2)治疗期间,试验组最高级别不良反应发生率显著低于对照组(χ~2=14.86,P<0.01);Ⅲ、Ⅳ级不良反应发生率分别为3.33%、13.33%(P>0.05)。(3)治疗后,试验组Karnofsky评分高于对照组[80(60,80)分vs 70(50,80)分,P<0.05]。(4)治疗后,试验组中医证候积分低于对照组[7.00(4.75,15.25)分vs 12.50(7.00,21.25)分,P<0.05]。(5)治疗后,试验组生存质量评分(躯体功能、总体健康状况、疲劳、恶心与呕吐和食欲丧失)优于对照组(P<0.05);两组患者角色、情绪、认知、社会功能评分比较,差异无统计学意义(P>0.05)。(6)两组患者客观缓解率(7.41%vs 3.40%)、疾病稳定率(81.48%vs 70.37%)比较,差异均无统计学意义(P>0.05)。结论:藿苏养胃口服液能有效降低阿帕替尼治疗进展期胃癌患者不良反应,提高患者生活质量。Objective:To observe the clinical efficacy of Huosu Yangwei Oral Liquid in the treatment of adverse reactions of advanced gastric cancer(AGC)with apatinib.Methods:64 AGC patients of Qi deficiency type were equally divided into the experimental group and the control group according to the random number table method.The control group was given apatinib,and the experimental group was given Huosu Yangwei Oral Liquid on the basis of the treatment of the control group.Both groups were treated for two courses(42 days),and the incidence of adverse reactions,quality of life,and DCR were compared between the two groups.Results:(1)During the treatment,the incidence of adverse reactions in the experimental group was lower than that in the control group(66.67%vs 90.00%,χ2=4.812,P<0.05).(2)During the treatment,the incidence of the highest-grade adverse reactions in the experimental group was significantly lower than that in the control group(χ2=14.86,P<0.01).And the incidences ofⅢ-Ⅳadverse reactions were 3.33%and 13.33%respectively(P>0.05).(3)After treatment,the Karnofsky score in the experimental group was higher than that in the control group[80(60,80)vs 70(50,80),P<0.05].(4)After treatment,the TCM syndrome score of the experimental group was lower than that of the control group[7.00(4.75,15.25)vs 12.50(7.00,21.25)],(P<0.05).(5)After treatment,the scores of life quality(physical function,general health,fatigue,nausea and vomiting,and loss of appetite)in the experimental group were better than those in the control group(P<0.05).There was no significant difference in the scores of role,emotion,cognition,and social function between the two groups(P>0.05).(6)There was no significant difference in ORR(7.41%vs 3.40%)and SD(81.48%vs 70.37%)between the two groups(P>0.05).Conclusion:Huosu Yangwei Oral Liquid can effectively reduce the adverse reactions of apatinib in AGC patients and improve their life quality.

关 键 词：胃癌 藿苏养胃口服液 阿帕替尼 脾气虚证 药物不良反应 生活质量 

分 类 号：R273.352[医药卫生—中西医结合]